[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Fennec Pharmaceuticals Inc (FENC)

Fennec Pharmaceuticals Inc (FENC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 312,588
  • Shares Outstanding, K 34,887
  • Annual Sales, $ 44,640 K
  • Annual Income, $ -9,740 K
  • EBIT $ -6 M
  • EBITDA $ -5 M
  • 60-Month Beta 1.08
  • Price/Sales 7.18
  • Price/Cash Flow N/A
  • Price/Book 8.43

Options Overview Details

View History
  • Implied Volatility 238.29% (-5.23%)
  • Historical Volatility 99.93%
  • IV Percentile 29%
  • IV Rank 28.38%
  • IV High 674.76% on 03/18/26
  • IV Low 65.31% on 06/23/25
  • Expected Move (DTE 1) 0.00 (0.00%)
  • Put/Call Vol Ratio 999.99
  • Today's Volume 4
  • Volume Avg (30-Day) 9
  • Put/Call OI Ratio 0.27
  • Today's Open Interest 594
  • Open Int (30-Day) 525
  • Expected Range 9.11 to 9.11

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $0.01
  • Number of Estimates 4
  • High Estimate $0.05
  • Low Estimate $-0.05
  • Prior Year $-0.11
  • Growth Rate Est. (year over year) +109.09%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.52 +7.25%
on 06/11/26
10.45 -12.61%
on 05/22/26
-0.62 (-6.33%)
since 05/15/26
3-Month
5.65 +61.64%
on 04/13/26
10.45 -12.61%
on 05/22/26
+1.37 (+17.69%)
since 03/17/26
52-Week
5.65 +61.64%
on 04/13/26
10.45 -12.61%
on 05/22/26
+1.41 (+18.30%)
since 06/17/25

Most Recent Stories

More News
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

RESEARCH TRIANGLE PARK, N.C., June 15, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced...

FRX.TO : 12.85 (+1.98%)
FENC : 9.21 (+2.79%)
Fennec Announces Results of Annual Meeting

RESEARCH TRIANGLE PARK, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy...

FRX.TO : 12.85 (+1.98%)
FENC : 9.21 (+2.79%)
Adherex Technologies’ PEDMARK Push Targets Larger AYA Market After Record Quarter

Fennec Pharmaceuticals (NASDAQ:FENC) executives outlined the company’s commercial strategy for PEDMARK, its sodium thiosulfate product used to prevent cisplatin-related hearing loss, during a fireside...

FENC : 9.21 (+2.79%)
Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting

~ Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK ® (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations ~ ~ Real-World...

FRX.TO : 12.85 (+1.98%)
FENC : 9.21 (+2.79%)
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., May 18, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced...

FRX.TO : 12.85 (+1.98%)
FENC : 9.21 (+2.79%)
Adherex Technologies Q1 Earnings Call Highlights

Adherex Technologies (NASDAQ:FENC) executives said Fennec Pharmaceuticals entered 2026 with stronger commercial momentum for PEDMARK, reporting higher first-quarter sales, positive operating cash flow...

FENC : 9.21 (+2.79%)
Fennec Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

~ Achieved First Quarter 2026 Total Net Revenues of $15.1 Million, Up 73% Year Over Year ~ ~ Field Sales Expansion Showing Early Signs of Positive Results with Record PEDMARK ® Demand in April...

FRX.TO : 12.85 (+1.98%)
FENC : 9.21 (+2.79%)
Fennec Pharmaceuticals to Report First Quarter 2026 Financial Results on May 14, 2026

RESEARCH TRIANGLE PARK, N.C., May 07, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company...

FRX.TO : 12.85 (+1.98%)
FENC : 9.21 (+2.79%)
Fennec Pharmaceuticals Announces Acceptance of Abstracts at the 2026 ASCO Annual Meeting

– Data from Four Studies Spotlight Rising Clinical Interest & Urgency to Address Cisplatin-Induced Hearing Loss and Its Lasting Impact on Patients – RESEARCH TRIANGLE PARK, N.C., April 21, 2026...

FRX.TO : 12.85 (+1.98%)
FENC : 9.21 (+2.79%)
Fennec Pharmaceuticals Announces Investigator-Sponsored Study to Be Conducted by University of Arizona Cancer Center

~ University of Arizona Cancer Center Initiating Study to Explore Use of PEDMARK ® in AYA & Adult Patients with Solid Tumors Receiving Cisplatin ~ ~ This New Study and Other Independent, Institution-Led...

FRX.TO : 12.85 (+1.98%)
FENC : 9.21 (+2.79%)

Business Summary

Fennec Pharmaceuticals Inc. is a clinical-stage biotechnology company. It is focused on the development of Sodium Thiosulfate for the prevention of ototoxicity from cisplatin in pediatric patients. The Company's products include Eniluracil and Sodium Thiosulfate (STS). Fennec Pharmaceuticals Inc., formerly...

See More

Key Turning Points

3rd Resistance Point 9.66
2nd Resistance Point 9.49
1st Resistance Point 9.23
Last Price 9.21
1st Support Level 8.80
2nd Support Level 8.63
3rd Support Level 8.37

See More

52-Week High 10.45
Last Price 9.21
Fibonacci 61.8% 8.62
Fibonacci 50% 8.05
Fibonacci 38.2% 7.48
52-Week Low 5.65

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.